Fig. 3From: Efficacy and acquired resistance of EGFR-TKI combined with chemotherapy as first-line treatment for Chinese patients with advanced non-small cell lung cancer in a real-world settingSubgroup analysis of progression-free survival HR: Hazard ratios; Del 19 del, exon 19 deletion; 21 L858R, exon 21 point mutation;T + C, EGFR-TKI combined with chemotherapy; T, EGFR-TKI monotherapyBack to article page